Home > Rheumatology > ACR 2019 > Spotlight on Rheumatoid Arthritis > Tocilizumab outperforms rituximab in RA patients with low level of synovial B cell infiltration

Tocilizumab outperforms rituximab in RA patients with low level of synovial B cell infiltration

Presented By
Prof. Costantino Pitzalis, Barts and The London School of Medicine and Dentistry, UK
Conference
ACR 2019
Tocilizumab is more effective than rituximab in achieving low disease activity (LDA) in rheumatoid arthritis (RA) patients refractory to conventional disease-modifying antirheumatic drugs (DMARDs) or TNF blockers, whose synovial tissue shows a low level of B cell infiltration [1]. “Approximately half of RA patients lack treatment responses to expensive biologic therapies that also carry the risk of side effects. Predictive markers of response could help stratify RA,” said Prof. Costantino Pitzalis (Barts and The London School of Medicine and Dentistry, United Kingdom). “This leaves a major unmet and urgent clinical need to identify markers of treatment response to avoid delays in disease control, unnecessary exposure to potentially toxic drugs, and considerable waste of resources.” B cells are pivotal to RA pathogenesis, validated by the efficacy of the B cell-depleting agent rituximab, which is approved for use in RA patients after inadequate response to ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on